Lantheus (LNTH) Competitors $52.94 -2.05 (-3.73%) Closing price 04:00 PM EasternExtended Trading$52.69 -0.25 (-0.47%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LNTH vs. VTRS, ASND, RDY, QGEN, BBIO, MRNA, ELAN, VRNA, ROIV, and RVMDShould you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Lantheus vs. Its Competitors Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories Qiagen BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Revolution Medicines Lantheus (NASDAQ:LNTH) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Do analysts rate LNTH or VTRS? Lantheus currently has a consensus target price of $91.60, suggesting a potential upside of 73.03%. Viatris has a consensus target price of $10.40, suggesting a potential upside of 4.42%. Given Lantheus' stronger consensus rating and higher probable upside, equities analysts plainly believe Lantheus is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Is LNTH or VTRS more profitable? Lantheus has a net margin of 17.82% compared to Viatris' net margin of -24.57%. Lantheus' return on equity of 34.06% beat Viatris' return on equity.Company Net Margins Return on Equity Return on Assets Lantheus17.82% 34.06% 19.10% Viatris -24.57%16.54%7.06% Do insiders & institutionals hold more shares of LNTH or VTRS? 99.1% of Lantheus shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 1.5% of Lantheus shares are held by insiders. Comparatively, 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better earnings and valuation, LNTH or VTRS? Lantheus has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.52B2.37$312.44M$3.7614.08Viatris$14.74B0.79-$634.20M-$2.90-3.43 Which has more volatility & risk, LNTH or VTRS? Lantheus has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Does the media refer more to LNTH or VTRS? In the previous week, Lantheus had 40 more articles in the media than Viatris. MarketBeat recorded 42 mentions for Lantheus and 2 mentions for Viatris. Viatris' average media sentiment score of 1.46 beat Lantheus' score of 0.53 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 8 Very Positive mention(s) 0 Positive mention(s) 29 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive Viatris 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLantheus beats Viatris on 13 of the 16 factors compared between the two stocks. Get Lantheus News Delivered to You Automatically Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNTH vs. The Competition Export to ExcelMetricLantheusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.60B$10.65B$5.79B$10.15BDividend YieldN/A1.85%5.69%4.60%P/E Ratio14.0821.1374.5925.92Price / Sales2.3731.03453.5485.33Price / Cash7.4024.7237.0859.91Price / Book3.383.5212.156.29Net Income$312.44M$210.50M$3.28B$270.77M7 Day Performance-3.31%-0.18%0.99%3.36%1 Month Performance-1.78%3.92%7.21%6.41%1 Year Performance-49.11%-10.02%63.07%28.24% Lantheus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNTHLantheus4.4911 of 5 stars$52.94-3.7%$91.60+73.0%-46.1%$3.60B$1.52B14.08700Trending NewsShort Interest ↓VTRSViatris1.6727 of 5 stars$10.55+1.3%$10.40-1.4%-10.3%$12.30B$14.12B-3.6432,000Positive NewsASNDAscendis Pharma A/S3.1612 of 5 stars$194.27+0.2%$243.36+25.3%+75.0%$11.89B$393.54M-37.651,017Positive NewsRDYDr. Reddy's Laboratories2.484 of 5 stars$14.20-0.1%$16.95+19.4%-7.1%$11.85B$3.81B21.5127,811Positive NewsQGENQiagen4.453 of 5 stars$46.53+0.9%$49.69+6.8%+3.3%$10.34B$2.04B27.495,765Positive NewsBBIOBridgeBio Pharma4.4552 of 5 stars$51.76-1.5%$62.18+20.1%+87.9%$9.89B$235.81M-12.66400Positive NewsAnalyst ForecastMRNAModerna4.4936 of 5 stars$24.09-1.6%$42.88+78.0%-68.1%$9.37B$3.06B-3.205,800Positive NewsELANElanco Animal Health2.6335 of 5 stars$18.38-0.4%$17.33-5.7%+29.8%$9.13B$4.48B21.379,000High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.1652 of 5 stars$105.91+0.0%$109.00+2.9%+252.9%$8.67B$221.67M-106.9830Positive NewsROIVRoivant Sciences2.9588 of 5 stars$11.93-0.1%$16.50+38.3%+16.4%$8.15B$29.05M-17.04860News CoveragePositive NewsOptions VolumeRVMDRevolution Medicines4.2417 of 5 stars$37.97-0.9%$69.92+84.2%+11.0%$7.10BN/A-8.44250Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies VTRS Competitors ASND Competitors RDY Competitors QGEN Competitors BBIO Competitors MRNA Competitors ELAN Competitors VRNA Competitors ROIV Competitors RVMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LNTH) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LNTH Stock Alerts